Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 10/20 | 0.49 |
| ▸ | REN | P00797 | 4/20 | 0.49 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PEPD | P12955 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29511796 | 0.95 | ACE (0.47) | ACERENCALCRL | |
| SCHEMBL30434786 | 0.89 | ACE (0.54) | ACERENLMNAKDM4EF2 | |
| SCHEMBL29379105 | 0.87 | ACE (0.47) | ACERENLMNAKDM4EF2 | |
| SCHEMBL29590519 | 0.87 | NAA50 (0.47) | ACERENCALCRLLMNADPP4 | |
| SCHEMBL30051485 | 0.87 | ACE (0.49) | ACERENLMNAKDM4EF2 | |
| SCHEMBL7758744 | 0.87 | ACE (0.64) | ACERENLMNAKDM4EF2 | |
| SCHEMBL31257002 | 0.85 | ACE (0.46) | ACERENLMNAKDM4EF2 | |
| SCHEMBL31257084 | 0.85 | ACE (0.50) | ACERENLMNAKDM4EF2 | |
| SCHEMBL31433173 | 0.85 | ACE (0.44) | ACERENLMNAKDM4EF2 | |
| SCHEMBL1323636 | 0.84 | ACE (0.56) | ACERENLMNAKDM4EF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055137-A1 | NOVEL ISOLATED PEPTIDES, PROTEIN HYDROLYSATE COMPRISING THE SAID ISOLATED PEPTIDES AND USE THEREOF | BETAGRO PUBLIC COMPANY LIMITED (TH) | 2026-02-26 | — | — | US | claimed |
| CN-119317364-A | Novel isolated peptides, protein hydrolysates comprising said isolated peptides and uses thereof | 丰年(大众)有限公司 | 2025-01-14 | — | — | CN | claimed |
| WO-2023218231-A1 | NOVEL ISOLATED PEPTIDES, PROTEIN HYDROLYSATE COMPRISING THE SAID ISOLATED PEPTIDES AND USE THEREOF | BETAGRO PUBLIC COMPANY LIMITED (TH) | 2023-11-16 | — | — | WO | claimed |
| US-20260055137-A1 | NOVEL ISOLATED PEPTIDES, PROTEIN HYDROLYSATE COMPRISING THE SAID ISOLATED PEPTIDES AND USE THEREOF | BETAGRO PUBLIC COMPANY LIMITED (TH) | 2026-02-26 | — | — | US | disclosed |
| US-20260055137-A1 | NOVEL ISOLATED PEPTIDES, PROTEIN HYDROLYSATE COMPRISING THE SAID ISOLATED PEPTIDES AND USE THEREOF | BETAGRO PUBLIC COMPANY LIMITED (TH) | 2026-02-26 | — | — | US | disclosed |
| JP-2025518505-A | — | ベタグロ パブリック カンパニー リミテッド | 2025-06-17 | — | — | JP | disclosed |
| CN-119317364-A | Novel isolated peptides, protein hydrolysates comprising said isolated peptides and uses thereof | 丰年(大众)有限公司 | 2025-01-14 | — | — | CN | disclosed |
| WO-2023218231-A1 | NOVEL ISOLATED PEPTIDES, PROTEIN HYDROLYSATE COMPRISING THE SAID ISOLATED PEPTIDES AND USE THEREOF | BETAGRO PUBLIC COMPANY LIMITED (TH) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055137-A1 | NOVEL ISOLATED PEPTIDES, PROTEIN HYDROLYSATE COMPRISING THE SAID ISOLATED PEPTIDES AND USE THEREOF | VIP, ARGLU1, PELP1 | ACE 1041/4885REN 541/4885CALCRL 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.